|
|
Corporate
-
Research & Development
Suven, US varsity in pact
Hyderabad, Oct. 26
Suven Life Sciences Ltd has entered into a
collaboration with the University of Minnesota,
Minneapolis, to develop new therapies to treat Human
Immunodeficiency Virus type 1 (HIV-1). The
Hyderabad-based company would cooperate with the
university in a research and test programme to explore
clinical efficacy of, and make available to patients,
under safe conditions, certain naturally occurring
substances that are believed to have therapeutic value
for HIV-1. "Current anti-retroviral therapy is not only
costly but also not accessible to many parts of the
world. Hence, a desperate worldwide need for
additional therapies to treat HIV-1 cost efficiently is
the need of the hour. - Our Bureau
More Stories on :
Research & Development |
Pharmaceuticals |
Education
Article
E-Mail
::
Comment
::
Syndication
::
Printer Friendly Page
|
Stories in this Section
Suven, US varsity in pact
L&T set to float $1-b infrastructure fund
3 bidders for ultra mega power projects in AP
Deccan Chronicle buyback plan
Bio-diesel plant using variety of materials as feedstock developed
Essar Steel completes buyout of Minnesota
BHEL venture with TNEB for Rs 8,500-cr project
Sun Pharma confident of closing Taro deal
Glenmark in marketing tie-up with MyerZall Labs
IOC-OIL scout for local partner to bid in Libya
Indian firms turn to Paraguay for farming
Closed tea gardens look for turnaround
Toyota open to using India as overseas production base
Kajaria Ceramics to expand Sikandrabad unit
Dr Reddy’s new pill to revitalise betapharm
Rupee appreciation has little impact on L&T
|
|
